Skip to main content

Table 3 Clinical activity and outcomes of the study group

From: Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at tertiary university hospital

Outcome

Activity (according to last visit)

n (%)

Disease activity (last JADAS-10 score)

Moderate disease activity (MDA)

4(28.6)

Low disease activity (LDA)

4(28.6)

Inactive

6(42.9)

Responders

Inactive and LDA

10(71.4)

Non-responders

MDA

4(28.6)

Outcome (ACR criteria)

Remission

4(28.6)

Remission on medication

5(35.7)

Active

5(35.7)

  1. Abbreviations: JADAS Juvenile Arthritis Disease Activity Score, ACR American College of Rheumatology